»Profit Hunter by Equitymaster

On This Day - 6 MAY 2020
A Stock that Will Beat the 40% Gains in the Pharma Sector Hands Down

When I think of it now, it seems quite eerie.

On the 31st of December 2019, I recorded a video, at the Equitymaster office. At that time, somewhere in Wuhan, China, one of the first cases of Coronavirus was getting confirmed.

My video - The One Sector Set for Big Rebound in 2020 and Beyond - was on the big potential of the Indian pharma sector in 2020.

But like everyone else, I had not even heard of coronavirus until then.

Indian pharma companies already had a terrible few years thanks to their USFDA woes. Earnings had been very volatile. Valuations were at rock bottom. So, my optimism about the sector was not founded on the basis of any potential global pandemic.

Coronavirus or not, I knew a few pharma companies in India were all set to rebound.

But coronavirus or Covid-19, proved India's importance to the world for low cost generic drug production. Billions of dollars are now being poured into vaccine research.

But the job of making billions of vaccine doses available will still rest with low cost vaccine manufacturers. Some of them will certainly be from Indian pharma.

It is therefore of little wonder that Indian pharma stocks went up 30% to 70% in the past two months.

The BSE Healthcare index gained 40% even as every other index bled.

But you would be wrong to assume that drug manufacturers will be the biggest gainers in a post Covid-19 world.

Rather, the technology that will help diagnose patients and prescribe drugs, world over, will see exponential growth.

And it answers to the name of Telemedicine.

{inlineads1}

Telemedicine basically means offering virtual healthcare when the doctor and patient are at remote locations.

The technology equips diagnostic tools like BP apparatus, ECG, glucometer etc with artificial intelligence. It helps doctors diagnose patients and prescribe medicines.

Traditionally, telemedicine has been associated with providing better healthcare access to under-served communities, rural populations, and low-income groups.

But Covid19 has made it a new normal for urban areas too.

One of the niche technology companies I've been tracking for the past five years, has been innovating in the telemedicine space for a while.

{inlineads2}

It has published research papers on integrating medical science with augmented and virtual reality, 3-D printing, robotics, and advanced IoT and AI capabilities.

In the last few quarters, the company has been investing heavily into this vertical.

I am confident the business is currently at an inflection point. Especially, for its agility in capturing the opportunities in the post Covid-19 world.

I have explained my rationale in detail, in my special report.

Looking at the potential upside in the stock, over a period of five to ten years, I believe investors could become a One Stock Crorepati.

Warm regards,

Tanushree Banerjee
Tanushree Banerjee
Editor, StockSelect
Equitymaster Agora Research Private Limited (Research Analyst)

PS: Find out more about this exciting stock here.

Copyright © Equitymaster Agora Research Private Limited. All rights reserved.

Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement

Disclosure & Disclaimer: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. The Author does not hold any shares in the company/ies discussed in this document. Equitymaster may hold shares in the company/ies discussed in this document under any of its other services.

This document is confidential and is supplied to you for information purposes only. It should not (directly or indirectly) be reproduced, further distributed to any person or published, in whole or in part, for any purpose whatsoever, without the consent of Equitymaster.

This document is not directed to, or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity, who is a citizen or resident or located in any locality, state, country or other jurisdiction, where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject Equitymaster or its affiliates to any registration or licensing requirement within such jurisdiction. If this document is sent or has reached any individual in such country, especially, USA, Canada or the European Union countries, the same may be ignored.

This document does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Our research recommendations are general in nature and available electronically to all kind of subscribers irrespective of subscribers' investment objectives and financial situation/risk profile. Before acting on any recommendation in this document, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. The price and value of the securities referred to in this material and the income from them may go down as well as up, and subscribers may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. Information herein is believed to be reliable but Equitymaster and its affiliates do not warrant its completeness or accuracy. The views/opinions expressed are our current opinions as of the date appearing in the material and may be subject to change from time to time without notice. This document should not be construed as an offer to sell or solicitation of an offer to buy any security or asset in any jurisdiction. Equitymaster and its affiliates, its directors, analyst and employees will not be responsible for any loss or liability incurred to any person as a consequence of his or any other person on his behalf taking any decisions based on this document.

As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407